|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
22
|
|
pubmed:dateCreated |
2010-7-30
|
|
pubmed:abstractText |
Pazopanib and lapatinib are tyrosine kinase inhibitors that target vascular endothelial growth factor receptor, platelet-derived growth factor receptor, and c-Kit or epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2/neu), respectively. In cervical cancer, EGFR and HER2/neu overexpression and high microvascular density correlate with survival.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Aug
|
|
pubmed:issn |
1527-7755
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
1
|
|
pubmed:volume |
28
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
3562-9
|
|
pubmed:meshHeading |
pubmed-meshheading:20606083-Adult,
pubmed-meshheading:20606083-Aged,
pubmed-meshheading:20606083-Aged, 80 and over,
pubmed-meshheading:20606083-Angiogenesis Inhibitors,
pubmed-meshheading:20606083-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:20606083-Disease-Free Survival,
pubmed-meshheading:20606083-Drug Delivery Systems,
pubmed-meshheading:20606083-Female,
pubmed-meshheading:20606083-Humans,
pubmed-meshheading:20606083-Middle Aged,
pubmed-meshheading:20606083-Protein Kinase Inhibitors,
pubmed-meshheading:20606083-Pyrimidines,
pubmed-meshheading:20606083-Quinazolines,
pubmed-meshheading:20606083-Recurrence,
pubmed-meshheading:20606083-Retreatment,
pubmed-meshheading:20606083-Sulfonamides,
pubmed-meshheading:20606083-Uterine Cervical Neoplasms
|
|
pubmed:year |
2010
|
|
pubmed:articleTitle |
Phase II, open-label study of pazopanib or lapatinib monotherapy compared with pazopanib plus lapatinib combination therapy in patients with advanced and recurrent cervical cancer.
|
|
pubmed:affiliation |
University of California Irvine Medical Center, Orange, CA 92868, USA. bjmonk@uci.edu
|
|
pubmed:publicationType |
Journal Article,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't,
Multicenter Study,
Clinical Trial, Phase II
|
